Stock Events

Stock Events

Amarin 

$14.46
94
+$0.51+3.66% Tuesday 20:00

Statistics

Day High
14.6
Day Low
14
52W High
20.9
52W Low
7.6
Volume
35,200
Avg. Volume
84,515
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

29OctExpected
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
-0.61
-0.34
-0.08
0.19
Expected EPS
-0.03
Actual EPS
0.19

Financials

-35.95%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
457.23MRevenue
-164.37MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AMRN. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca competes with Amarin in the cardiovascular drug market, particularly with drugs aimed at reducing triglyceride levels and improving heart health.
AMGEN
AMGN
Mkt Cap160.66B
Amgen offers a range of cardiovascular treatments that directly compete with Amarin's Vascepa, especially in the high triglyceride management space.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline competes in the cardiovascular and metabolic disease areas, offering alternative treatments that could be used instead of Amarin's products.
Merck
MRK
Mkt Cap214.76B
Merck & Co. has a portfolio of cardiovascular drugs that can be seen as alternatives to Amarin's offerings, particularly in the lipid management space.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad range of cardiovascular drugs that compete with Amarin, including treatments for conditions that Vascepa is prescribed for.
Novartis
NVS
Mkt Cap237.61B
Novartis competes with Amarin in the heart health market, with drugs that offer similar benefits to Vascepa in reducing cardiovascular risk.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, through its broad portfolio in the pharmaceutical sector, competes in the cardiovascular space, offering treatments that could serve as alternatives to Amarin's products.
Sanofi
SNY
Mkt Cap124.45B
Sanofi has a presence in the cardiovascular disease treatment market, competing with Amarin with its range of heart health medications.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, in partnership with Sanofi, develops drugs that compete in the same therapeutic areas as Amarin, including cardiovascular health.

About

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Show more...
CEO
Mr. Aaron D. Berg
Employees
275
Country
US
ISIN
US0231114044

Listings

F
DE
EH3.F
BOATS
BOATS
AMRN.BOATS
XNAS
US
AMRN

0 Comments

Share your thoughts

FAQ

What is Amarin stock price today?▼
The current price of AMRN is $14.46 USD — it has increased by +3.66% in the past 24 hours. Watch Amarin stock price performance more closely on the chart.
What is Amarin stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Amarin stocks are traded under the ticker AMRN.
Is Amarin stock price growing?▼
AMRN stock has fallen by -1.5% compared to the previous week, the month change is a +4.78% rise, over the last year Amarin has showed a +3,171.49% increase.
What were Amarin earnings last quarter?▼
AMRN earnings for the last quarter are 0.19 USD per share, whereas the estimation was -0.03 USD resulting in a +733.33% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Amarin revenue for the last year?▼
Amarin revenue for the last year amounts to 457.23M USD.
What is Amarin net income for the last year?▼
AMRN net income for the last year is -164.37M USD.
How many employees does Amarin have?▼
As of April 01, 2026, the company has 275 employees.
In which sector is Amarin located?▼
Amarin operates in the Health Care sector.
When did Amarin complete a stock split?▼
The last stock split for Amarin was on April 11, 2025 with a ratio of 1:20.
Where is Amarin headquartered?▼
Amarin is headquartered in Dublin, US.